Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
- Klíčová slova
- Drospirenone, oestrogen-free contraception, progestins, spirolactone derivative,
- MeSH
- androsteny farmakologie MeSH
- inhibice ovulace účinky léků MeSH
- klinické zkoušky jako téma MeSH
- kontraceptiva orální farmakologie MeSH
- lidé MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- androsteny MeSH
- drospirenone MeSH Prohlížeč
- kontraceptiva orální MeSH
Purpose: The contraceptive pill is an effective and safe method of preventing pregnancy. The progestins used for contraception either are components of a combined hormonal contraceptive (tablets, patches or vaginal rings) or are used alone in progestin-only formulations. Progestin-only contraceptives are available as daily oral preparations, subcutaneous or intramuscular injectables (every 1-3 months), subdermal implants (every 3-5 years) and intrauterine systems (every 3-5 years). Long-acting progestins are highly effective in typical use and have a very low risk profile and few contraindications.Material and Methods: A new progestin-only, oestrogen-free contraceptive, drospirenone, in a dosage of 4 mg/day in a 24/4 regimen, has received regulatory approval in the USA and the EU. The molecule has antigonadotropic, antimineralocorticoid, antiestrogenic and antiandrogenic properties.Results: The regimen was chosen to improve the bleeding profile; maintain plasma oestradiol levels at those of the early follicular phase, to avoid hypoestrogenism; and preserve efficacy even with a missed pill, as drospirenone has a half-life of 30-34 h.Conclusions: Clinical studies have shown good efficacy, very low cardiovascular side effects and a favourable bleeding pattern, as well as maintenance of ovulation inhibition after scheduled 24 h delays in pill intake.
Center for Reproductive Health Institute of Mother and Child Warsaw Poland
Clinic for Obstetrics and Gynecology University Hospital Basel Basel Switzerland
Department for Gynecology and Obstetrics Gynecole com rue Saint Honoré Paris France
Department for Gynecology VL Medi Clinical Research Center Helsinki Finland
Department of Gynecology and Obstetrics Palacios Institute of Women's Health Madrid Spain
Department of Obstetrics and Gynaecology Ghent University Hospital Ghent Belgium
Department of Obstetrics and Gynaecology Semmelweis University Budapest Hungary
Department of Obstetrics and Gynaecology University Hospital of Cologne Cologne Germany
Faculty of Health and Medical Sciences University of Copenhagen Denmark
Medical Department Exeltis Europe Ismaning Germany
Obstetrics and Gynaecology Clinic G CENTRUM Olomouc Olomouc Czech Republic
Citace poskytuje Crossref.org
